Aura Biosciences (AURA) Cash from Financing Activities (2020 - 2026)

Aura Biosciences (AURA) has 7 years of Cash from Financing Activities data on file, last reported at $300000.0 in Q1 2026.

• Quarterly Cash from Financing Activities rose 212.5% year-over-year to $300000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.4 million (up 5279.62% YoY) and the FY2025 annual result came in at $77.2 million, up 4737.3% from the prior year.
• Cash from Financing Activities declined to $300000.0 in Q1 2026, from $2.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $95.2 million in Q4 2022 to a low of $17000.0 in Q1 2022.
• A 5-year average of $16.0 million and a median of $543000.0 in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 99.98% — and 2025, when it surged 84151.81%.
• Tracing AURA's Cash from Financing Activities over 5 years: stood at $95.2 million in 2022, then declined by 2.33% to $93.0 million in 2023, then plunged by 99.42% to $543000.0 in 2024, then soared by 409.58% to $2.8 million in 2025, then tumbled by 89.16% to $300000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $300000.0 (Q1 2026), $2.8 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.